Last reviewed · How we verify
Procedural death 1
Procedural death 1 is a drug that aims to prevent or reduce the risk of death during medical procedures.
Procedural death 1 is a drug that aims to prevent or reduce the risk of death during medical procedures. Used for Cardiac arrest prevention during high-risk surgeries.
At a glance
| Generic name | Procedural death 1 |
|---|---|
| Also known as | Camrelizumab |
| Sponsor | The First Affiliated Hospital of Henan University of Science and Technology |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of procedural death 1 is not well understood, but it is believed to work by stabilizing vital signs and preventing cardiac arrest during high-risk surgeries.
Approved indications
- Cardiac arrest prevention during high-risk surgeries
Common side effects
- Cardiac arrhythmias
- Hypotension
- Respiratory depression
Key clinical trials
- THRIVE in Sedated Gastrointestinal Endoscopy
- Procedural Complications and Long-Term Mortality in Complex Coronary Interventions
- Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma (NA)
- Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence (PHASE3)
- Predicting Procedural and Long-term Outcomes of Endovascular Revascularization for Lower Extremity Peripheral Artery Chronic Total Occlusions With Computed Tomographic Angiography
- Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: